Veracyte, Inc.VCYTNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-1.74%
↓ 106% below average
Average (39q)
26.77%
Historical baseline
Range
High:341.39%
Low:-75.08%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -1.74% |
| Q2 2025 | -8.22% |
| Q1 2025 | -8.14% |
| Q4 2024 | 9.76% |
| Q3 2024 | 6.74% |
| Q2 2024 | 3.13% |
| Q1 2024 | -14.50% |
| Q4 2023 | 40.17% |
| Q3 2023 | 6.23% |
| Q2 2023 | -1.79% |
| Q1 2023 | 13.13% |
| Q4 2022 | 4.77% |
| Q3 2022 | 14.89% |
| Q2 2022 | 2.30% |
| Q1 2022 | -63.51% |
| Q4 2021 | 213.78% |
| Q3 2021 | 28.12% |
| Q2 2021 | 17.11% |
| Q1 2021 | 16.35% |
| Q4 2020 | 341.39% |
| Q3 2020 | -75.08% |
| Q2 2020 | -5.40% |
| Q1 2020 | -0.81% |
| Q4 2019 | 21.96% |
| Q3 2019 | 9.40% |
| Q2 2019 | -3.06% |
| Q1 2019 | 9.92% |
| Q4 2018 | 165.28% |
| Q3 2018 | -46.77% |
| Q2 2018 | 109.37% |
| Q1 2018 | -66.99% |
| Q4 2017 | 278.04% |
| Q3 2017 | -37.63% |
| Q2 2017 | -20.68% |
| Q1 2017 | -52.31% |
| Q4 2016 | 95.64% |
| Q3 2016 | -16.02% |
| Q2 2016 | 46.35% |
| Q1 2016 | -55.34% |
| Q4 2015 | 95.04% |